We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

44 hedge funds and large institutions have $1.68M invested in Relmada Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.22% less ownership

Funds ownership: 27.84% → 20.61% (-7.2%)

8% less funds holding

Funds holding: 48 → 44 (-4)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

62% less capital invested

Capital invested by funds: $4.36M → $1.68M (-$2.68M)

71% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 14

Holders
44
Holders Change
-4
Holders Change %
-8.33%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
4
Reduced
14
Closed
12
Calls
$20K
Puts
–
Net Calls
+$20K
Net Calls Change
-$189K

Top Buyers

1
Goldman Sachs
Goldman Sachs
New York
+$40.1K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$29.5K
3
AI
AdvisorShares Investments
Maryland
+$22K
4
HF
HRT Financial
New York
+$17.3K
5
Two Sigma Investments
Two Sigma Investments
New York
+$14.2K

Top Sellers

1
Franklin Resources
Franklin Resources
California
-$417K
2
TCM
Tang Capital Management
California
-$104K
3
Barclays
Barclays
United Kingdom
-$75.9K
4
GCP
GSA Capital Partners
United Kingdom
-$65K
5
Bank of America
Bank of America
North Carolina
-$64K
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
1
Acadian Asset Management
Massachusetts
$329K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$326K -$16.1K -48,630 -4%
BlackRock
3
BlackRock
New York
$153K -$8.76K -26,421 -4%
PAI
4
Palo Alto Investors
California
$134K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$81.5K -$317 -955 -0.3%
Two Sigma Advisers
6
Two Sigma Advisers
New York
$77.8K +$29.5K +89,100 +45%
AI
7
AdvisorShares Investments
Maryland
$75.7K +$22K +66,446 +32%
Deutsche Bank
8
Deutsche Bank
Germany
$60.7K – – –
Two Sigma Investments
9
Two Sigma Investments
New York
$46K +$14.2K +42,965 +34%
PCM
10
Parsons Capital Management
Rhode Island
$44.1K – – –
RC
11
RBF Capital
California
$44.1K – – –
UBS Group
12
UBS Group
Switzerland
$39.1K -$23.3K -70,351 -33%
Renaissance Technologies
13
Renaissance Technologies
New York
$33.5K -$13.4K -40,413 -25%
Goldman Sachs
14
Goldman Sachs
New York
$32.6K +$40.1K +120,852 New
State Street
15
State Street
Massachusetts
$28.8K – – –
MOS
16
MGO One Seven
Ohio
$27K – – –
Northern Trust
17
Northern Trust
Illinois
$16.1K -$8.19K -24,711 -29%
HF
18
HRT Financial
New York
$14K +$17.3K +52,043 New
AW
19
Apricus Wealth
South Carolina
$13.2K – – –
Franklin Resources
20
Franklin Resources
California
$11.6K -$417K -1,259,354 -97%
IC
21
Ikarian Capital
Texas
$10.9K – – –
SEI Investments
22
SEI Investments
Pennsylvania
$9.78K – – –
AG
23
AlTi Global
New York
$8.63K – – –
Group One Trading
24
Group One Trading
Illinois
$7.73K -$24.3K -73,446 -72%
WIA
25
Wealthedge Investment Advisors
New York
$7.56K – – –
1
2 3

RLMD Hedge Fund Activity: Q1 2025 in Review

44 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2025, worth a combined $1.68M — down 62% from $4.36M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of RLMD and 8 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 4 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $40.1K. The largest seller was Franklin Resources, cutting an estimated $417K.

  • 44 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2025, down from 48 in Q4 2024.
  • Funds reported $1.68M of Relmada Therapeutics stock for Q1 2025, down 62% quarter-over-quarter.
  • 8 funds opened new Relmada Therapeutics positions in Q1 2025 and 12 closed out, a net change of -4 holders.
  • The largest Relmada Therapeutics buyer in Q1 2025 was Goldman Sachs, an estimated $40.1K added.
  • The largest Relmada Therapeutics seller in Q1 2025 was Franklin Resources, an estimated $417K sold.

Based on aggregated 13F filings for Q1 2025.